Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (20)	1/8/2003 10:21:40 AM
From: gg cox	Read Replies (1) \| Respond to of 66

biz.yahoo.com IMI and McNeil expand marketing partnership for heart disease predictive test Friday December 20, 1:14 pm ET Partnership now includes North American insurance laboratory market TORONTO, Dec. 20 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) announced today that it has expanded its marketing partnership with McNeil Consumer Healthcare to include the laboratory market for insurance testing throughout the U.S., Canada and Mexico. "The market for insurance testing represents a significant new opportunity for our predictive heart disease test throughout North America," said Dr. Brent Norton, IMI President and CEO. "Millions of insurance policies are granted each year without a cardiovascular risk assessment, and now through our simple skin test McNeil can begin to exploit that strategic opportunity." "Our relationship with McNeil continues to grow. Together we are building toward market launches and developing new test formats for specific market opportunities to maximize the potential for the technology," said Dr. Norton. About IMI IMI is a world leader in predictive medicine. IMI is dedicated to developing rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer. IMI's lead product is a non-invasive skin test for coronary artery disease. IMI's cancer products in development include ColorectAlert(TM), a screening test for colorectal cancer, and LungAlert(TM), a screening test for lung cancer, and a new test for breast cancer. For further information, please visit the company's web site at www.imimedical.com. This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. For further information Andrew Weir, Director, Communications, (416) 222-3449 x27, aweir@imimedical.com Richard Land, Karin Oloffson, Jaffoni & Collins Incorporated, (212) 835-8500 or imi@jcir.com